임상

HOME > 연구실적 > 임상 > 논문
 
작성일 : 16-03-13 21:45
논문번호 47
논문제목(영문) The Long-Term Clinical Results of a Platelet Glycoprotein IIb/IIIa Receptor Blocker (Abciximab：ReoPro®) Coated Stent in Patients with Acute Myocardial Infarction.
국내외구분 국내 SCI여부 SCI(E)
연구책임자역할 교신저자
주저자명 Kim W
교신저자명 Jeong MH
공동저자명 Kim W, Jeong MH, Hong YJ, Park HW, Lee MG, Jeong SY, Kim IS, Kim KH, Yoon KH, Kang DG, Hong SN, LimSY, Lee SH, Lee YS, Kim JH, Ahn YK, Cho JG, Park JC, Kim H, Cho DL, Kang JC;
게제년월일 2004-07-25
ISSN 1738-5520
Impact Factor 0.753
학술지명 Korean Circulation J
서지사항 0집 / 34권 / 11호,   페이지(1063 - 1069)
요약초록문
(Abstract) 입력		 Background and Objectives：The inhibition of coronary restenosis with an Abciximab (ReoPro®)-coated stent has previously been reported by us. This study investigated the clinical outcomes of patients with acute myocardial infarction (AMI) treated with ReoPro-coated stents.
Subjects and Method：A prospective randomized trial was conducted to compare two types of stent for the revascularization in 63 patients [Group I (ReoPro®- coated stent)：n=32, 53.7±11.8 years, 27 male, and Group II (control stent)：n=31, 55.4±12.1 years, 27 male] with AMI. The primary effective end points were major adverse coronary events (MACE)：cardiac death, acute myocardial infarction, target lesion revascularization (TLR), in-stent restenosis and late lumen loss at the 1 year clinical and angiographic follow-ups.
Results：Baseline clinical characteristics and diameters of stenosis and the minimal luminal diameters were no different between the two groups. There was one myocardial infarction and revascularization during the hospital stay in group II. Follow-up coronary angiograms were performed in 71.9 (23/32) and 77.4% (24/31) of groups I and II, respectively. The diameter of stenosis and late loss were significantly lower in group I than group II (19.4±5.1 vs. 34.8±5.9%, p=0.013；and 0.39±0.26 vs. 0.89±0.45 mm；p=0.008, respectively). However, the restenosis rates were no different between the two groups (21.7 vs. 37.5%, p=0.341). One year clinical follow-ups were possible in 98.4% (62/63), and there were two AMI found in group II, but none in group I. The TLR rates and total MACE of group I were relatively lower compared with group II [12.9 (4/31) vs. 29.0% (9/31)；p=0.122 and 12.9 (4/31) vs. 35.5% (11/31), p=0.038, respectively].
Conclusion：The ReoPro®-coated stent was safe, with no stent thrombosis, and effective in patients with AMI.
파일  C47. Korean Circulation J 2004;34(11)1063-1069..pdf (447.3K) DATE : 2016-03-21 11:09:07